[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Global Enterobacteriaceae Infection Drug Market Size, Status and Forecast 2020-2026

August 2020 | 95 pages | ID: GE80E84ACC80EN
QYResearch

US$ 3,900.00

E-mail Delivery (PDF)

Download PDF Leaflet

Accepted cards
Wire Transfer
Checkout Later
Need Help? Ask a Question
This report focuses on the global Enterobacteriaceae Infection Drug status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Enterobacteriaceae Infection Drug development in North America, Europe and Asia-Pacific.

The key players covered in this study
  • Genentech
  • Nanotherapeutics
  • Novartis
  • Pfizer
  • Nymox Pharmaceutical
  • Sequoia Sciences
  • Phico Therapeutics
  • Cantab Biopharmaceuticals
Market segment by Type, the product can be split into
  • Beta-lactams Drugs
  • Carbapenems Drugs
  • Fluoroquinolones Drugs
  • Others
Market segment by Application, split into
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
Market segment by Regions/Countries, this report covers
  • North America
  • Europe
  • Asia-Pacific
The study objectives of this report are:
  • To analyze global Enterobacteriaceae Infection Drug status, future forecast, growth opportunity, key market and key players.
  • To present the Enterobacteriaceae Infection Drug development in North America, Europe and Asia-Pacific.
  • To strategically profile the key players and comprehensively analyze their development plan and strategies.
  • To define, describe and forecast the market by type, market and key regions.
In this study, the years considered to estimate the market size of Enterobacteriaceae Infection Drug are as follows:
  • History Year: 2015-2019
  • Base Year: 2019
  • Estimated Year: 2020
  • Forecast Year 2020 to 2026
For the data information by region, company, type and application, 2019 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.
1 REPORT OVERVIEW

1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Enterobacteriaceae Infection Drug Revenue
1.4 Market Analysis by Type
  1.4.1 Global Enterobacteriaceae Infection Drug Market Size Growth Rate by Type: 2020 VS 2026
  1.4.2 Beta-lactams Drugs
  1.4.3 Carbapenems Drugs
  1.4.4 Fluoroquinolones Drugs
  1.4.5 Others
1.5 Market by Application
  1.5.1 Global Enterobacteriaceae Infection Drug Market Share by Application: 2020 VS 2026
  1.5.2 Hospital Pharmacies
  1.5.3 Retail Pharmacies
  1.5.4 Online Pharmacies
1.6 Coronavirus Disease 2019 (Covid-19): Enterobacteriaceae Infection Drug Industry Impact
  1.6.1 How the Covid-19 is Affecting the Enterobacteriaceae Infection Drug Industry
    1.6.1.1 Enterobacteriaceae Infection Drug Business Impact Assessment - Covid-19
    1.6.1.2 Supply Chain Challenges
    1.6.1.3 COVID-19’s Impact On Crude Oil and Refined Products
  1.6.2 Market Trends and Enterobacteriaceae Infection Drug Potential Opportunities in the COVID-19 Landscape
  1.6.3 Measures / Proposal against Covid-19
    1.6.3.1 Government Measures to Combat Covid-19 Impact
    1.6.3.2 Proposal for Enterobacteriaceae Infection Drug Players to Combat Covid-19 Impact
1.7 Study Objectives
1.8 Years Considered

2 GLOBAL GROWTH TRENDS BY REGIONS

2.1 Enterobacteriaceae Infection Drug Market Perspective (2015-2026)
2.2 Enterobacteriaceae Infection Drug Growth Trends by Regions
  2.2.1 Enterobacteriaceae Infection Drug Market Size by Regions: 2015 VS 2020 VS 2026
  2.2.2 Enterobacteriaceae Infection Drug Historic Market Share by Regions (2015-2020)
  2.2.3 Enterobacteriaceae Infection Drug Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
  2.3.1 Market Top Trends
  2.3.2 Market Drivers
  2.3.3 Market Challenges
  2.3.4 Porter’s Five Forces Analysis
  2.3.5 Enterobacteriaceae Infection Drug Market Growth Strategy
  2.3.6 Primary Interviews with Key Enterobacteriaceae Infection Drug Players (Opinion Leaders)

3 COMPETITION LANDSCAPE BY KEY PLAYERS

3.1 Global Top Enterobacteriaceae Infection Drug Players by Market Size
  3.1.1 Global Top Enterobacteriaceae Infection Drug Players by Revenue (2015-2020)
  3.1.2 Global Enterobacteriaceae Infection Drug Revenue Market Share by Players (2015-2020)
  3.1.3 Global Enterobacteriaceae Infection Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.2 Global Enterobacteriaceae Infection Drug Market Concentration Ratio
  3.2.1 Global Enterobacteriaceae Infection Drug Market Concentration Ratio (CR5 and HHI)
  3.2.2 Global Top 10 and Top 5 Companies by Enterobacteriaceae Infection Drug Revenue in 2019
3.3 Enterobacteriaceae Infection Drug Key Players Head office and Area Served
3.4 Key Players Enterobacteriaceae Infection Drug Product Solution and Service
3.5 Date of Enter into Enterobacteriaceae Infection Drug Market
3.6 Mergers & Acquisitions, Expansion Plans

4 BREAKDOWN DATA BY TYPE (2015-2026)

4.1 Global Enterobacteriaceae Infection Drug Historic Market Size by Type (2015-2020)
4.2 Global Enterobacteriaceae Infection Drug Forecasted Market Size by Type (2021-2026)

5 ENTEROBACTERIACEAE INFECTION DRUG BREAKDOWN DATA BY APPLICATION (2015-2026)

5.1 Global Enterobacteriaceae Infection Drug Market Size by Application (2015-2020)
5.2 Global Enterobacteriaceae Infection Drug Forecasted Market Size by Application (2021-2026)

6 NORTH AMERICA

6.1 North America Enterobacteriaceae Infection Drug Market Size (2015-2020)
6.2 Enterobacteriaceae Infection Drug Key Players in North America (2019-2020)
6.3 North America Enterobacteriaceae Infection Drug Market Size by Type (2015-2020)
6.4 North America Enterobacteriaceae Infection Drug Market Size by Application (2015-2020)

7 EUROPE

7.1 Europe Enterobacteriaceae Infection Drug Market Size (2015-2020)
7.2 Enterobacteriaceae Infection Drug Key Players in Europe (2019-2020)
7.3 Europe Enterobacteriaceae Infection Drug Market Size by Type (2015-2020)
7.4 Europe Enterobacteriaceae Infection Drug Market Size by Application (2015-2020)

8 ASIA-PACIFIC

8.1 Asia-Pacific Enterobacteriaceae Infection Drug Market Size (2015-2020)
8.2 Enterobacteriaceae Infection Drug Key Players in Asia-Pacific (2019-2020)
8.3 Asia-Pacific Enterobacteriaceae Infection Drug Market Size by Type (2015-2020)
8.4 Asia-Pacific Enterobacteriaceae Infection Drug Market Size by Application (2015-2020)
(2015-2020)
(2015-2020)

9 KEY PLAYERS PROFILES

9.1 Genentech
  9.1.1 Genentech Company Details
  9.1.2 Genentech Business Overview and Its Total Revenue
  9.1.3 Genentech Enterobacteriaceae Infection Drug Introduction
  9.1.4 Genentech Revenue in Enterobacteriaceae Infection Drug Business (2015-2020))
  9.1.5 Genentech Recent Development
9.2 Nanotherapeutics
  9.2.1 Nanotherapeutics Company Details
  9.2.2 Nanotherapeutics Business Overview and Its Total Revenue
  9.2.3 Nanotherapeutics Enterobacteriaceae Infection Drug Introduction
  9.2.4 Nanotherapeutics Revenue in Enterobacteriaceae Infection Drug Business (2015-2020)
  9.2.5 Nanotherapeutics Recent Development
9.3 Novartis
  9.3.1 Novartis Company Details
  9.3.2 Novartis Business Overview and Its Total Revenue
  9.3.3 Novartis Enterobacteriaceae Infection Drug Introduction
  9.3.4 Novartis Revenue in Enterobacteriaceae Infection Drug Business (2015-2020)
  9.3.5 Novartis Recent Development
9.4 Pfizer
  9.4.1 Pfizer Company Details
  9.4.2 Pfizer Business Overview and Its Total Revenue
  9.4.3 Pfizer Enterobacteriaceae Infection Drug Introduction
  9.4.4 Pfizer Revenue in Enterobacteriaceae Infection Drug Business (2015-2020)
  9.4.5 Pfizer Recent Development
9.5 Nymox Pharmaceutical
  9.5.1 Nymox Pharmaceutical Company Details
  9.5.2 Nymox Pharmaceutical Business Overview and Its Total Revenue
  9.5.3 Nymox Pharmaceutical Enterobacteriaceae Infection Drug Introduction
  9.5.4 Nymox Pharmaceutical Revenue in Enterobacteriaceae Infection Drug Business (2015-2020)
  9.5.5 Nymox Pharmaceutical Recent Development
9.6 Sequoia Sciences
  9.6.1 Sequoia Sciences Company Details
  9.6.2 Sequoia Sciences Business Overview and Its Total Revenue
  9.6.3 Sequoia Sciences Enterobacteriaceae Infection Drug Introduction
  9.6.4 Sequoia Sciences Revenue in Enterobacteriaceae Infection Drug Business (2015-2020)
  9.6.5 Sequoia Sciences Recent Development
9.7 Phico Therapeutics
  9.7.1 Phico Therapeutics Company Details
  9.7.2 Phico Therapeutics Business Overview and Its Total Revenue
  9.7.3 Phico Therapeutics Enterobacteriaceae Infection Drug Introduction
  9.7.4 Phico Therapeutics Revenue in Enterobacteriaceae Infection Drug Business (2015-2020)
  9.7.5 Phico Therapeutics Recent Development
9.8 Cantab Biopharmaceuticals
  9.8.1 Cantab Biopharmaceuticals Company Details
  9.8.2 Cantab Biopharmaceuticals Business Overview and Its Total Revenue
  9.8.3 Cantab Biopharmaceuticals Enterobacteriaceae Infection Drug Introduction
  9.8.4 Cantab Biopharmaceuticals Revenue in Enterobacteriaceae Infection Drug Business (2015-2020)
  9.8.5 Cantab Biopharmaceuticals Recent Development

10 ANALYST'S VIEWPOINTS/CONCLUSIONS

11 APPENDIX

11.1 Research Methodology
  11.1.1 Methodology/Research Approach
  11.1.2 Data Source
11.2 Disclaimer
11.3 Author Details
LIST OF TABLES

Table 1. Enterobacteriaceae Infection Drug Key Market Segments
Table 2. Key Players Covered: Ranking by Enterobacteriaceae Infection Drug Revenue
Table 3. Ranking of Global Top Enterobacteriaceae Infection Drug Manufacturers by Revenue (US$ Million) in 2019
Table 4. Global Enterobacteriaceae Infection Drug Market Size Growth Rate by Type (US$ Million): 2020 VS 2026
Table 5. Key Players of Beta-lactams Drugs
Table 6. Key Players of Carbapenems Drugs
Table 7. Key Players of Fluoroquinolones Drugs
Table 8. Key Players of Others
Table 9. COVID-19 Impact Global Market: (Four Enterobacteriaceae Infection Drug Market Size Forecast Scenarios)
Table 10. Opportunities and Trends for Enterobacteriaceae Infection Drug Players in the COVID-19 Landscape
Table 11. Present Opportunities in China & Elsewhere Due to the Coronavirus Crisis
Table 12. Key Regions/Countries Measures against Covid-19 Impact
Table 13. Proposal for Enterobacteriaceae Infection Drug Players to Combat Covid-19 Impact
Table 14. Global Enterobacteriaceae Infection Drug Market Size Growth by Application (US$ Million): 2020 VS 2026
Table 15. Global Enterobacteriaceae Infection Drug Market Size by Regions (US$ Million): 2020 VS 2026
Table 16. Global Enterobacteriaceae Infection Drug Market Size by Regions (2015-2020) (US$ Million)
Table 17. Global Enterobacteriaceae Infection Drug Market Share by Regions (2015-2020)
Table 18. Global Enterobacteriaceae Infection Drug Forecasted Market Size by Regions (2021-2026) (US$ Million)
Table 19. Global Enterobacteriaceae Infection Drug Market Share by Regions (2021-2026)
Table 20. Market Top Trends
Table 21. Key Drivers: Impact Analysis
Table 22. Key Challenges
Table 23. Enterobacteriaceae Infection Drug Market Growth Strategy
Table 24. Main Points Interviewed from Key Enterobacteriaceae Infection Drug Players
Table 25. Global Enterobacteriaceae Infection Drug Revenue by Players (2015-2020) (Million US$)
Table 26. Global Enterobacteriaceae Infection Drug Market Share by Players (2015-2020)
Table 27. Global Top Enterobacteriaceae Infection Drug Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Enterobacteriaceae Infection Drug as of 2019)
Table 28. Global Enterobacteriaceae Infection Drug by Players Market Concentration Ratio (CR5 and HHI)
Table 29. Key Players Headquarters and Area Served
Table 30. Key Players Enterobacteriaceae Infection Drug Product Solution and Service
Table 31. Date of Enter into Enterobacteriaceae Infection Drug Market
Table 32. Mergers & Acquisitions, Expansion Plans
Table 33. Global Enterobacteriaceae Infection Drug Market Size by Type (2015-2020) (Million US$)
Table 34. Global Enterobacteriaceae Infection Drug Market Size Share by Type (2015-2020)
Table 35. Global Enterobacteriaceae Infection Drug Revenue Market Share by Type (2021-2026)
Table 36. Global Enterobacteriaceae Infection Drug Market Size Share by Application (2015-2020)
Table 37. Global Enterobacteriaceae Infection Drug Market Size by Application (2015-2020) (Million US$)
Table 38. Global Enterobacteriaceae Infection Drug Market Size Share by Application (2021-2026)
Table 39. North America Key Players Enterobacteriaceae Infection Drug Revenue (2019-2020) (Million US$)
Table 40. North America Key Players Enterobacteriaceae Infection Drug Market Share (2019-2020)
Table 41. North America Enterobacteriaceae Infection Drug Market Size by Type (2015-2020) (Million US$)
Table 42. North America Enterobacteriaceae Infection Drug Market Share by Type (2015-2020)
Table 43. North America Enterobacteriaceae Infection Drug Market Size by Application (2015-2020) (Million US$)
Table 44. North America Enterobacteriaceae Infection Drug Market Share by Application (2015-2020)
Table 45. Europe Key Players Enterobacteriaceae Infection Drug Revenue (2019-2020) (Million US$)
Table 46. Europe Key Players Enterobacteriaceae Infection Drug Market Share (2019-2020)
Table 47. Europe Enterobacteriaceae Infection Drug Market Size by Type (2015-2020) (Million US$)
Table 48. Europe Enterobacteriaceae Infection Drug Market Share by Type (2015-2020)
Table 49. Europe Enterobacteriaceae Infection Drug Market Size by Application (2015-2020) (Million US$)
Table 50. Europe Enterobacteriaceae Infection Drug Market Share by Application (2015-2020)
Table 51. Asia-Pacific Key Players Enterobacteriaceae Infection Drug Revenue (2019-2020) (Million US$)
Table 52. Asia-Pacific Key Players Enterobacteriaceae Infection Drug Market Share (2019-2020)
Table 53. Asia-Pacific Enterobacteriaceae Infection Drug Market Size by Type (2015-2020) (Million US$)
Table 54. Asia-Pacific Enterobacteriaceae Infection Drug Market Share by Type (2015-2020)
Table 55. Asia-Pacific Enterobacteriaceae Infection Drug Market Size by Application (2015-2020) (Million US$)
Table 56. Asia-Pacific Enterobacteriaceae Infection Drug Market Share by Application (2015-2020)
Table 57. Genentech Company Details
Table 58. Genentech Business Overview
Table 59. Genentech Product
Table 60. Genentech Revenue in Enterobacteriaceae Infection Drug Business (2015-2020) (Million US$)
Table 61. Genentech Recent Development
Table 62. Nanotherapeutics Company Details
Table 63. Nanotherapeutics Business Overview
Table 64. Nanotherapeutics Product
Table 65. Nanotherapeutics Revenue in Enterobacteriaceae Infection Drug Business (2015-2020) (Million US$)
Table 66. Nanotherapeutics Recent Development
Table 67. Novartis Company Details
Table 68. Novartis Business Overview
Table 69. Novartis Product
Table 70. Novartis Revenue in Enterobacteriaceae Infection Drug Business (2015-2020) (Million US$)
Table 71. Novartis Recent Development
Table 72. Pfizer Company Details
Table 73. Pfizer Business Overview
Table 74. Pfizer Product
Table 75. Pfizer Revenue in Enterobacteriaceae Infection Drug Business (2015-2020) (Million US$)
Table 76. Pfizer Recent Development
Table 77. Nymox Pharmaceutical Company Details
Table 78. Nymox Pharmaceutical Business Overview
Table 79. Nymox Pharmaceutical Product
Table 80. Nymox Pharmaceutical Revenue in Enterobacteriaceae Infection Drug Business (2015-2020) (Million US$)
Table 81. Nymox Pharmaceutical Recent Development
Table 82. Sequoia Sciences Company Details
Table 83. Sequoia Sciences Business Overview
Table 84. Sequoia Sciences Product
Table 85. Sequoia Sciences Revenue in Enterobacteriaceae Infection Drug Business (2015-2020) (Million US$)
Table 86. Sequoia Sciences Recent Development
Table 87. Phico Therapeutics Company Details
Table 88. Phico Therapeutics Business Overview
Table 89. Phico Therapeutics Product
Table 90. Phico Therapeutics Revenue in Enterobacteriaceae Infection Drug Business (2015-2020) (Million US$)
Table 91. Phico Therapeutics Recent Development
Table 92. Cantab Biopharmaceuticals Business Overview
Table 93. Cantab Biopharmaceuticals Product
Table 94. Cantab Biopharmaceuticals Company Details
Table 95. Cantab Biopharmaceuticals Revenue in Enterobacteriaceae Infection Drug Business (2015-2020) (Million US$)
Table 96. Cantab Biopharmaceuticals Recent Development
Table 97. Research Programs/Design for This Report
Table 98. Key Data Information from Secondary Sources
Table 99. Key Data Information from Primary Sources

LIST OF FIGURES

Figure 1. Global Enterobacteriaceae Infection Drug Market Share by Type: 2020 VS 2026
Figure 2. Beta-lactams Drugs Features
Figure 3. Carbapenems Drugs Features
Figure 4. Fluoroquinolones Drugs Features
Figure 5. Others Features
Figure 6. Global Enterobacteriaceae Infection Drug Market Share by Application: 2020 VS 2026
Figure 7. Hospital Pharmacies Case Studies
Figure 8. Retail Pharmacies Case Studies
Figure 9. Online Pharmacies Case Studies
Figure 10. Enterobacteriaceae Infection Drug Report Years Considered
Figure 11. Global Enterobacteriaceae Infection Drug Market Size YoY Growth 2015-2026 (US$ Million)
Figure 12. Global Enterobacteriaceae Infection Drug Market Share by Regions: 2020 VS 2026
Figure 13. Global Enterobacteriaceae Infection Drug Market Share by Regions (2021-2026)
Figure 14. Porter's Five Forces Analysis
Figure 15. Global Enterobacteriaceae Infection Drug Market Share by Players in 2019
Figure 16. Global Top Enterobacteriaceae Infection Drug Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Enterobacteriaceae Infection Drug as of 2019
Figure 17. The Top 10 and 5 Players Market Share by Enterobacteriaceae Infection Drug Revenue in 2019
Figure 18. North America Enterobacteriaceae Infection Drug Market Size YoY Growth (2015-2020) (Million US$)
Figure 19. Europe Enterobacteriaceae Infection Drug Market Size YoY Growth (2015-2020) (Million US$)
Figure 20. Asia-Pacific Enterobacteriaceae Infection Drug Market Size YoY Growth (2015-2020) (Million US$)
Figure 21. Genentech Total Revenue (US$ Million): 2019 Compared with 2018
Figure 22. Genentech Revenue Growth Rate in Enterobacteriaceae Infection Drug Business (2015-2020)
Figure 23. Nanotherapeutics Total Revenue (US$ Million): 2019 Compared with 2018
Figure 24. Nanotherapeutics Revenue Growth Rate in Enterobacteriaceae Infection Drug Business (2015-2020)
Figure 25. Novartis Total Revenue (US$ Million): 2019 Compared with 2018
Figure 26. Novartis Revenue Growth Rate in Enterobacteriaceae Infection Drug Business (2015-2020)
Figure 27. Pfizer Total Revenue (US$ Million): 2019 Compared with 2018
Figure 28. Pfizer Revenue Growth Rate in Enterobacteriaceae Infection Drug Business (2015-2020)
Figure 29. Nymox Pharmaceutical Total Revenue (US$ Million): 2019 Compared with 2018
Figure 30. Nymox Pharmaceutical Revenue Growth Rate in Enterobacteriaceae Infection Drug Business (2015-2020)
Figure 31. Sequoia Sciences Total Revenue (US$ Million): 2019 Compared with 2018
Figure 32. Sequoia Sciences Revenue Growth Rate in Enterobacteriaceae Infection Drug Business (2015-2020)
Figure 33. Phico Therapeutics Total Revenue (US$ Million): 2019 Compared with 2018
Figure 34. Phico Therapeutics Revenue Growth Rate in Enterobacteriaceae Infection Drug Business (2015-2020)
Figure 35. Cantab Biopharmaceuticals Total Revenue (US$ Million): 2019 Compared with 2018
Figure 36. Cantab Biopharmaceuticals Revenue Growth Rate in Enterobacteriaceae Infection Drug Business (2015-2020)
Figure 37. Bottom-up and Top-down Approaches for This Report
Figure 38. Data Triangulation
Figure 39. Key Executives Interviewed


More Publications